129 related articles for article (PubMed ID: 35045942)
1. Five-Year Clinical Outcomes of the COBRA Polyzene F NanoCoated Coronary Stent System.
Cutlip DE; Jauhar R; Meraj P; Garratt KN; Novack V; Novack L; Maillard L; Erglis A; Stoler R; Barakat M; Silber S;
Cardiovasc Revasc Med; 2022 Aug; 41():76-80. PubMed ID: 35045942
[TBL] [Abstract][Full Text] [Related]
2. 9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System.
Cutlip DE; Garratt KN; Novack V; Barakat M; Meraj P; Maillard L; Erglis A; Jauhar R; Popma JJ; Stoler R; Silber S;
JACC Cardiovasc Interv; 2017 Jan; 10(2):160-167. PubMed ID: 28104210
[TBL] [Abstract][Full Text] [Related]
3. MAPT (Mono Antiplatelet Therapy) as Regular Regimen After COBRA PzF™ NanoCoated Coronary Stent (NCS) Implantation.
Maillard L; Vochelet F; Peycher P; Ayari A; Barra N; Billé J; Joly P; Silvestri M; Sévilla J; Tavildari A
Cardiovasc Revasc Med; 2020 Jun; 21(6):785-789. PubMed ID: 31780418
[TBL] [Abstract][Full Text] [Related]
4. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the safety and efficacy of the Cobra PzF NanoCoated coronary stent in routine, consecutive, prospective, and high-risk patients: The e-Cobra study.
Maillard L; de Labriolle A; Brasselet C; Faurie B; Durel N; de Poli F; Bosle S; Madiot H; Berland J; Belle L
Catheter Cardiovasc Interv; 2021 Jul; 98(1):45-54. PubMed ID: 32548891
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the safety and efficacy of a Polyzene-F nanocoated coronary stent system: A systematic review and single-arm meta-analysis.
Bian J; Yang R; Wang D; Yu H; Liu Y; Liu Q
Front Cardiovasc Med; 2023; 10():1095794. PubMed ID: 37008338
[TBL] [Abstract][Full Text] [Related]
7. The EXTREME registry: titanium-nitride-oxide coated stents in small coronary arteries.
Valdesuso R; Karjalainen P; García J; Díaz J; Portales JF; Masotti M; Picó F; Serra A; Burgos JM; Insa L; Mauri F; Collado JR; Nammas W
Catheter Cardiovasc Interv; 2010 Aug; 76(2):281-7. PubMed ID: 20665878
[TBL] [Abstract][Full Text] [Related]
8. Immediate and 1-year follow-up with the novel nanosurface modified COBRA PzF stent.
Maillard L; Tavildari A; Barra N; Billé J; Joly P; Peycher P; Silvestri M; Vochelet F
Arch Cardiovasc Dis; 2017 Dec; 110(12):682-688. PubMed ID: 29102364
[TBL] [Abstract][Full Text] [Related]
9. Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions.
Abdel-Wahab M; Baev R; Dieker P; Kassner G; Khattab AA; Toelg R; Sulimov D; Geist V; Richardt G
Catheter Cardiovasc Interv; 2013 Feb; 81(2):285-91. PubMed ID: 22431433
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
11. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
[TBL] [Abstract][Full Text] [Related]
12. 5-Year clinical follow-up of the COBRA (complex coronary bifurcation lesions: Randomized comparison of a strategy using a dedicated self-expanding biolimus A9-eluting stent vs. a culotte strategy using everolimus-eluting stents) study.
Bennett J; Adriaenssens T; McCutcheon K; Dens J; Desmet W; Sinnaeve P; Vrolix M; Dubois C
Catheter Cardiovasc Interv; 2018 Nov; 92(6):E375-E380. PubMed ID: 29536609
[TBL] [Abstract][Full Text] [Related]
13. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
14. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
Kandzari DE; Koolen JJ; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
JACC Cardiovasc Interv; 2020 Jun; 13(11):1343-1353. PubMed ID: 32499026
[TBL] [Abstract][Full Text] [Related]
15. Everolimus Eluting Stents in Patients with Diabetes Mellitus and Chronic Kidney Disease: Insights from the TUXEDO Trial.
Bangalore S; Abhaichand R; Mullasari A; Jain R; Chand RKP; Arambam P; Kaul U
Cardiovasc Revasc Med; 2019 Dec; 20(12):1075-1080. PubMed ID: 31036397
[TBL] [Abstract][Full Text] [Related]
16. Orbital atherectomy for treating de novo, severely calcified coronary lesions: 3-year results of the pivotal ORBIT II trial.
Lee M; Généreux P; Shlofmitz R; Phillipson D; Anose BM; Martinsen BJ; Himmelstein SI; Chambers JW
Cardiovasc Revasc Med; 2017 Jun; 18(4):261-264. PubMed ID: 28162989
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of titanium-nitride-oxide-coated cobalt-chromium stents in patients with de novo coronary lesions: 12-month results of the OPTIMAX first-in-man study.
Karjalainen PP; Mikkelsson J; Paana T; Nammas W
Catheter Cardiovasc Interv; 2016 Mar; 87(4):E122-7. PubMed ID: 26308878
[TBL] [Abstract][Full Text] [Related]
18. Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA I trial.
Xu B; Dou K; Yang Y; Lv S; Wang L; Wang H; Li Z; Wang L; Chen Y; Huo Y; Li W; Kirtane AJ; Gao R
EuroIntervention; 2012 Nov; 8(7):796-802. PubMed ID: 23171800
[TBL] [Abstract][Full Text] [Related]
19. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
